Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2015.02.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RecA deletion disrupts protein homeostasis, leading to deamidation, oxidation, and impaired glycolysis in .
Appl Environ Microbiol
December 2024
School of Medicine, Nankai University, Tianjin, Tianjin, China.
is a foodborne pathogen linked to severe infections in infants and often associated with contaminated powdered infant formula. The RecA protein, a key player in DNA repair and recombination, also influences bacterial resilience and virulence. This study investigated the impact of deletion on the pathogenicity and environmental stress tolerance of BAA-894.
View Article and Find Full Text PDFLubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.
Aliment Pharmacol Ther
January 2025
Liver Unit, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Background And Aims: The laxative lubiprostone has been shown to decrease intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone administered for 48 weeks in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Approach And Results: A randomised placebo-controlled trial was conducted in a specialised MASLD outpatient clinic at the National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report.
Front Immunol
January 2025
Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Background: Radical cystectomy (RC) combined with pelvic lymph node dissection (PLND) is the standard treatment for muscle-invasive bladder cancer (MIBC). For metastatic MIBC patients, platinum-based chemotherapy remains the first choice treatment. However, approximately 50% of patients with metastatic MIBC are ineligible for platinum-based adjuvant chemotherapy because of impaired renal function.
View Article and Find Full Text PDFAnalysis of the short-term efficacy of 2 versus 3 cycles of neoadjuvant immunotherapy combined with chemotherapy in patients with esophageal squamous cell carcinoma.
J Cancer
January 2025
Department of Thoracic Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Neoadjuvant immunotherapy combined with chemotherapy has a substantial impact on locally advanced esophageal squamous cell carcinoma (LA-ESCC), but the optimal number of treatment cycles is still controversial. Patients who received 2 or 3 cycles of neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy to treat LA-ESCC were included. We compared the responses to neoadjuvant therapy, surgical outcomes, perioperative complications, and treatment-related adverse reactions in the two patient groups.
View Article and Find Full Text PDFSingle-fraction high-dose-rate brachytherapy as monotherapy for localized prostate cancer: long-term follow-up study based on meta-analysis.
J Cancer
January 2025
Department of Radiation Oncology, Nanyang Central Hospital, Nanyang, Henan, 473005, China.
Although single-fraction high-dose-rate brachytherapy (SFHDR-BT) for localized prostate cancer has been attempted in clinical trials, there is currently a lack of relevant medical evidence. It is essential to conduct a systematic analysis of the long-term safety and efficacy of SFHDR-BT. Comprehensive and systematic searches for eligible studies were performed in PubMed, Embase, and the Cochrane Library databases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!